Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dis-Chem PharmaciesJSE:DCP -2.10%86 EV-to-EBIT is 16.07 as of Aug. 19, 2026, which is 15% below its 10-year median of 18.81. GuruFocus rates JSE:DCP with a GF Score™ of 86/100 and a GF Value™ of R38.56 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 474 Healthcare Providers & Services companies, Dis-Chem Pharmacies ranks worse than 50.21% on this metric.
The historical rank and industry rank for Dis-Chem Pharmacies's EV-to-EBIT or its related term are showing as below:
JSE:DCP'
s EV-to-EBIT Range Over the Past 10 Years
Min: 13.47 Med: 18.81 Max: 37.69
Current: 16.07
During the past 13 years, the highest EV-to-EBIT of Dis-Chem Pharmacies was 37.69. The lowest was 13.47. And the median was 18.81.
JSE:DCP's EV-to-EBIT is ranked worse than 50.21% of 474
companies
in the Healthcare Providers & Services industry
Industry Median: 15.98
vs JSE:DCP: 16.07
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Dis-Chem Pharmacies's Enterprise Value for the quarter that ended in Feb. 2026 was R37,863 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dis-Chem Pharmacies's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 was R1,949 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dis-Chem Pharmacies EV-to-EBIT Related Terms
Dis-Chem Pharmacies EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Dis-Chem Pharmacies's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Dis-Chem Pharmacies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dis-Chem Pharmacies EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Dis-Chem Pharmacies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dis-Chem Pharmacies's EV-to-EBIT falls into.
Dis-Chem Pharmacies's current Enterprise Value is R31,323 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Dis-Chem Pharmacies's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 was R1,949 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dis-Chem Pharmacies (JSE:DCP) has a EV-to-EBIT of 16.07 as of Aug. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dis-Chem Pharmacies and its competitors. This is 15% below median its historical median of 18.81. Over the past decade, Dis-Chem Pharmacies' EV-to-EBIT has ranged from 13.47 to 37.69. According to the industry distribution chart, Dis-Chem Pharmacies ranks #238 out of 474 companies in the Healthcare Providers & Services industry, placing it in the top 50.2%.
Is Dis-Chem Pharmacies' EV-to-EBIT too high?
Dis-Chem Pharmacies' current EV-to-EBIT of 16.07 is 15% below median its 10-year median of 18.81. Over the past 10 years, this metric has ranged from a low of 13.47 to a high of 37.69. The Healthcare Providers & Services industry median EV-to-EBIT is 15.98. Dis-Chem Pharmacies' value of 16.07 is 0.6% above this industry median. Based on the distribution chart, Dis-Chem Pharmacies ranks #238 out of 474 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Dis-Chem Pharmacies has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dis-Chem Pharmacies' EV-to-EBIT compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Dis-Chem Pharmacies ranks #238 out of 474 companies for EV-to-EBIT. This places Dis-Chem Pharmacies in the lower half of its industry. The industry median EV-to-EBIT is 15.98. Dis-Chem Pharmacies' value of 16.07 is 0.6% above this benchmark. Historically, Dis-Chem Pharmacies' own EV-to-EBIT has ranged from 13.47 to 37.69 over the past decade. While the company's 10-year median is 18.81 vs. the industry median of 15.98, Dis-Chem Pharmacies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.98, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dis-Chem Pharmacies's current EV-to-EBIT of 16.07 is 0.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dis-Chem Pharmacies and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dis-Chem Pharmacies's current EV-to-EBIT is 16.07, which is 15% below median its own 10-year median of 18.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dis-Chem Pharmacies stock overvalued right now?
Based on GuruFocus' analysis, Dis-Chem Pharmacies (JSE:DCP) is currently considered Modestly Undervalued. The stock's GF Value™ is R38.56, compared to a current price of R29.36 — trading 23.9% below its estimated fair value. The current EV-to-EBIT is 16.07, which is 15% below median its 10-year median of 18.81 and 0.6% above the Healthcare Providers & Services industry median of 15.98. Dis-Chem Pharmacies' overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Dis-Chem Pharmacies (JSE:DCP), the current EV-to-EBIT is 16.07 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dis-Chem Pharmacies (JSE:DCP) Overvalued in 2026?
Based on GuruFocus' analysis, Dis-Chem Pharmacies stock appears to be undervalued.
The current stock price of R29.36 is trading 23.9% below its estimated GF Value™ of R38.56.
GuruFocus considers Dis-Chem Pharmacies to be Modestly Undervalued.
Key valuation signals for JSE:DCP:
EV-to-EBIT: 16.07 (15% below median its 10-year median of 18.81)
GF Value™: R38.56 vs. price of R29.36 (23.9% below fair value)
Industry Position: 0.6% above the Healthcare Providers & Services median (#238 of 474)
No single metric tells the full story. See the JSE:DCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dis-Chem Pharmacies Ltd is a pharmaceutical company based in South Africa. Its product portfolio includes personal care products, beauty products, healthcare and nutrition products, and dispensary and baby care products. The operating segments of the group are Retail and Wholesale. It derives maximum revenue from the Retail segment, which includes company stores, retailers of pharmaceuticals and a variety of health and beauty products, as well as pharma-logistic services and oncology and retailers of pharmaceutical products. The Wholesale segment consists of the CJ wholesale and company distribution businesses, wholesalers of pharmaceuticals, and a variety of health and beauty products. Geographically, the group carries out its business operations principally in South Africa.
86GF Score
Get the complete analysis for JSE:DCP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:DCP has been successfully added to your 
